{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesenchymal+Tumor&page=4", "query": { "condition": "Mesenchymal Tumor", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 78, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesenchymal+Tumor&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesenchymal+Tumor&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T07:47:20.854Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03608631", "title": "iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS NP_004976.2:p.G12D", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-01-27", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03608631" }, { "nct_id": "NCT02221882", "title": "A Study of LY3164530 in Participants With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3164530", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-08", "completion_date": "2017-03-07", "has_results": true, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02221882" }, { "nct_id": "NCT07181681", "title": "A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-C0902", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2025-11-10", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07181681" }, { "nct_id": "NCT05176665", "title": "EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis", "Metastatic Gastrointestinal Carcinoid Tumor" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2021-10-21", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176665" }, { "nct_id": "NCT03797391", "title": "A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis", "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2018-12-13", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Canton, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797391" }, { "nct_id": "NCT03147976", "title": "QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "AMG 337", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NantPharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-02", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147976" }, { "nct_id": "NCT01697072", "title": "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Rilotumumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 609, "start_date": "2012-10", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 16, "location_summary": "Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697072" }, { "nct_id": "NCT00354744", "title": "High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 109, "start_date": "2006-07", "completion_date": "2019-06-30", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 143, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00354744" }, { "nct_id": "NCT07048314", "title": "Stem Cells for Erectile Dysfunction Post RALP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Erectile Dysfunction", "Prostate Cancer" ], "interventions": [ { "name": "Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office", "type": "DRUG" }, { "name": "Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR", "type": "DRUG" }, { "name": "Placebo in the OR", "type": "DRUG" }, { "name": "Placebo in clinic", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "40 Years to 70 Years · Male only" }, "enrollment_count": 40, "start_date": "2026-07-07", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07048314" }, { "nct_id": "NCT06669117", "title": "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "MET Alteration" ], "interventions": [ { "name": "VERT-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2024-10-22", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-10-05T07:47:20.854Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Canton", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06669117" } ] }